Title: Abstract B70: Decitabine, the DNA demethylating agent, works in solid tumor patients by promoting the proliferation and lysis activity of T lymphocytes
Abstract:Abstract Epigenetic alterations, such as DNA methylation, play crucial roles in cancer development and metastasis. Epigenetic therapy has been approved in hematological malignancies treatment, while i...Abstract Epigenetic alterations, such as DNA methylation, play crucial roles in cancer development and metastasis. Epigenetic therapy has been approved in hematological malignancies treatment, while its application in solid tumors is ongoing and the clinical function mechanism is not clear. Clinical trials using the demethylating agent decitabine on solid tumor patients have been undertaken in our department of biological therapy. Notably, low dose decitabine treatment significantly enhanced the activation and proliferation of the peripheral T cells both in vitro and in vivo. Moreover, the cytotoxic ability of peripheral T cells was increased with a marked enhancement in Th1 response post the epigenetic therapy. The sequencing analysis confirmed the enrichment for pathways in cell cycle, mitosis, immune response and methylation after decitabine treatment. Our findings provided the molecular evidences that the DNA demethylating agent treatment could promote the anti-tumor capacity of T cells in solid tumor patients. Citation Format: Nie Jing. Decitabine, the DNA demethylating agent, works in solid tumor patients by promoting the proliferation and lysis activity of T lymphocytes. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr B70.Read More
Publication Year: 2016
Publication Date: 2016-01-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot